{"id":440,"date":"2026-07-06T13:54:16","date_gmt":"2026-07-06T13:54:16","guid":{"rendered":"https:\/\/www.altrx.com\/blogs\/?p=440"},"modified":"2026-07-06T13:54:18","modified_gmt":"2026-07-06T13:54:18","slug":"semaglutide-cut-heart-attack-risk-by-20-in-people-without-diabetes-here-is-what-the-select-trial-found","status":"publish","type":"post","link":"https:\/\/www.altrx.com\/blogs\/semaglutide-cut-heart-attack-risk-by-20-in-people-without-diabetes-here-is-what-the-select-trial-found\/","title":{"rendered":"Semaglutide Cut Heart Attack Risk by 20% in People Without Diabetes. Here Is What the SELECT Trial Found."},"content":{"rendered":"\n

Tony, a 59-year-old retiree from Phoenix, had his first heart attack at 55. His cardiologist put him on a statin, aspirin, and a beta-blocker. He lost 12 pounds through diet changes. Then life got busy, and the weight came back. By 2023 he was carrying 247 pounds on a 5\u201910″ frame, a BMI of 35.4.<\/p>\n\n\n\n

His cardiologist brought up Wegovy. Not for the weight, or at least not only for the weight. \u201cShe said there was a trial that showed it actually reduces heart attacks in people like me,\u201d Tony recalled. \u201cI thought she was talking about a diabetes drug.\u201d<\/p>\n\n\n\n

She wasn\u2019t. The trial his cardiologist was referencing had just been published in the New England Journal of Medicine and had changed how cardiologists think about a drug most people still associate with weight loss.<\/p>\n\n\n\n

The SELECT Trial: What It Studied and Why It Matters<\/a><\/h2>\n\n\n\n

The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial, known as SELECT, was not a weight loss study. It was a cardiovascular outcomes trial designed around one question: does semaglutide 2.4 mg reduce the incidence of serious heart events in overweight or obese adults who already have cardiovascular disease, but do not have diabetes?<\/p>\n\n\n\n

That distinction is critical. Prior cardiovascular outcomes trials for GLP-1 medications, including LEADER and SUSTAIN-6, enrolled patients with type 2 diabetes. Their cardiovascular benefits were significant, but they left open the question of whether the drug itself was doing the work or whether better blood sugar control was the driver. SELECT removed diabetes from the equation entirely.<\/p>\n\n\n\n

The trial enrolled 17,604 adults<\/strong> across 41 countries. All participants had a BMI of 27 or above, pre-existing cardiovascular disease (prior heart attack, prior stroke, or symptomatic peripheral arterial disease), and no history of diabetes. Participants were randomized to semaglutide 2.4 mg weekly or placebo. Median follow-up was 3.3 years\u00b9.<\/p>\n\n\n\n

The Results<\/a><\/h2>\n\n\n\n

The primary endpoint was a composite of major adverse cardiovascular events: cardiovascular death, nonfatal heart attack, or nonfatal stroke.<\/p>\n\n\n\n

The results, published in the New England Journal of Medicine in November 2023:<\/p>\n\n\n\n

Outcome<\/td>Semaglutide<\/td>Placebo<\/td>Hazard Ratio<\/td><\/tr>
MACE (primary endpoint)<\/td>6.5%<\/td>8.0%<\/td>0.80 (95% CI 0.72-0.90)<\/td><\/tr>
Cardiovascular death<\/td>2.5%<\/td>3.0%<\/td>0.85 (95% CI 0.71-1.01)<\/td><\/tr>
Nonfatal heart attack<\/td>3.6%<\/td>4.8%<\/td>0.72 (95% CI 0.61-0.85)<\/td><\/tr>
Nonfatal stroke<\/td>1.3%<\/td>1.5%<\/td>0.81 (95% CI 0.60-1.08)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

A 20% relative risk reduction in major cardiovascular events<\/strong> (HR 0.80, 95% CI 0.72-0.90, p less than 0.001). The number needed to treat to prevent one cardiovascular event over 3.3 years was approximately 67 patients.<\/p>\n\n\n\n

The benefit appeared consistent across subgroups, including age, sex, body weight, and region. Importantly, it emerged well before meaningful weight loss had accumulated, raising questions about whether the mechanism extends beyond adiposity reduction alone\u00b2.<\/p>\n\n\n\n

The FDA Response: A New Indication<\/a><\/h2>\n\n\n\n

In March 2024, the FDA approved Wegovy (semaglutide 2.4 mg) for the reduction of serious cardiovascular events in adults with established cardiovascular disease and overweight or obesity, making it the first weight loss medication to ever receive a cardiovascular risk reduction indication.<\/p>\n\n\n\n

This matters clinically and symbolically. For decades, weight loss drugs were approved purely on the basis of weight outcomes. SELECT changed the regulatory framing: semaglutide is now approved not only to reduce body weight, but to reduce the likelihood that a patient with heart disease dies from it or has another event.<\/p>\n\n\n\n

For prescribing physicians, this creates a new category of patient who has a clear indication for semaglutide even when weight loss is not the primary goal.<\/p>\n\n\n\n

How Might GLP-1 Protect the Heart?<\/a><\/h2>\n\n\n\n

Weight loss is part of the story, but probably not all of it.<\/p>\n\n\n\n

Inflammation reduction.<\/strong> Systemic inflammation drives atherosclerotic plaque development and instability. GLP-1 receptor activation has demonstrated direct anti-inflammatory effects on vascular endothelium and macrophages within atherosclerotic plaques, independent of weight changes. In SELECT, participants receiving semaglutide showed reductions in high-sensitivity CRP (a key inflammatory marker) that exceeded what weight loss alone would predict\u00b3.<\/p>\n\n\n\n

Blood pressure and lipid improvements.<\/strong> Across SELECT, semaglutide-treated participants showed modest but consistent reductions in systolic blood pressure and improvements in lipid profiles, both established cardiovascular risk factors.<\/p>\n\n\n\n

Direct cardiac effects.<\/strong> GLP-1 receptors are expressed on cardiomyocytes and vascular smooth muscle. Pre-clinical studies suggest GLP-1 receptor activation may improve cardiac function directly, reduce oxidative stress in cardiac tissue, and promote favorable remodeling after ischemic injury. These mechanisms are active research areas; they have not been definitively established in humans.<\/p>\n\n\n\n

Plaque stabilization.<\/strong> Some researchers hypothesize that GLP-1 receptor activation stabilizes atherosclerotic plaques, making them less likely to rupture and cause acute events. This is consistent with the early divergence of event curves in SELECT, which began separating before substantial weight loss was achieved.<\/p>\n\n\n\n

What SELECT Does and Doesn\u2019t Tell Us<\/a><\/h2>\n\n\n\n

What it shows:<\/strong> Semaglutide 2.4 mg produces a clinically meaningful, statistically robust reduction in major cardiovascular events in people with obesity and established cardiovascular disease who do not have diabetes. This benefit is real and FDA-recognized.<\/p>\n\n\n\n

What it doesn\u2019t show:<\/strong> SELECT does not establish whether semaglutide prevents a first cardiovascular event in lower-risk populations. The trial enrolled patients with established CVD, not those with risk factors only. The cardiovascular benefit in primary prevention settings remains an open research question.<\/p>\n\n\n\n

Tirzepatide:<\/strong> The SURMOUNT-CVOT trial is examining tirzepatide\u2019s cardiovascular effects and will provide comparable data for the dual GLP-1\/GIP agonist within the next several years. SELECT\u2019s findings cannot be automatically extended to tirzepatide.<\/p>\n\n\n\n

Weight loss is still meaningful:<\/strong> Even setting aside cardiovascular outcomes, the SELECT participants lost an average of 9.4% of body weight at two years on semaglutide versus 0.9% on placebo. For someone at Tony\u2019s starting weight, that\u2019s approximately 23 pounds of real weight loss with real metabolic benefits.<\/p>\n\n\n\n

Who Should Be Having This Conversation With Their Doctor?<\/a><\/h2>\n\n\n\n

The SELECT population is a specific group: adults with BMI 27 or above and a prior cardiovascular event (heart attack, stroke, or symptomatic peripheral artery disease), without type 2 diabetes. These patients now have an FDA-approved cardiovascular indication for semaglutide, not just an obesity treatment rationale.<\/p>\n\n\n\n

If you have a prior heart attack or stroke, carry excess weight, and are not diabetic, SELECT established that semaglutide can reduce your risk of another event. That conversation belongs in the cardiologist\u2019s office as much as the primary care office.<\/p>\n\n\n\n

For patients already on semaglutide for weight or metabolic reasons who also have established CVD: the SELECT data suggests you may be receiving cardiovascular protection alongside the metabolic benefit, something worth discussing with your cardiologist when reviewing your overall risk management plan.<\/p>\n\n\n\n

Key Takeaway<\/a><\/h2>\n\n\n\n

SELECT enrolled 17,604 adults with obesity and pre-existing cardiovascular disease but no diabetes, and found that semaglutide 2.4 mg produced a 20% relative risk reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) over 3.3 years versus placebo. In March 2024, the FDA approved Wegovy for cardiovascular risk reduction, the first time a weight loss medication has received this designation. The benefit likely reflects a combination of weight loss, inflammation reduction, blood pressure improvement, and possible direct vascular effects. For patients with established cardiovascular disease and obesity who are not diabetic, semaglutide now carries a cardiovascular indication, not just a weight loss one.<\/p>\n\n\n\n

Category<\/em><\/p>\n\n\n\n

GLP-1, Semaglutide, Cardiovascular Risk, Heart Attack, SELECT Trial, Wegovy, Obesity, Heart Disease, MACE, FDA Approval, Cardiovascular Outcomes<\/p>\n\n\n\n

References<\/em><\/p>\n\n\n\n

\u00b9 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232.<\/p>\n\n\n\n

\u00b2 SELECT trial subgroup analyses and early event curve divergence. New England Journal of Medicine supplementary data. 2023.<\/p>\n\n\n\n

\u00b3 Anti-inflammatory mechanisms of GLP-1 receptor agonism: vascular endothelium, macrophage polarization, and CRP reduction. Journal of the American College of Cardiology. 2024.<\/p>\n\n\n\n

\u2074 FDA approves Wegovy for reduction of cardiovascular events in adults with obesity or overweight and established cardiovascular disease. FDA Press Release. March 8, 2024.<\/p>\n\n\n\n

\u2075 GLP-1 receptor expression in cardiomyocytes and vascular smooth muscle: pre-clinical and translational evidence for direct cardiac effects. Circulation. 2023.<\/p>\n\n\n\n

Disclaimer<\/strong><\/p>\n\n\n\n

This article is for educational purposes only and is not medical advice. Semaglutide\u2019s cardiovascular indication applies specifically to adults with established cardiovascular disease and overweight or obesity without type 2 diabetes. Individual cardiovascular risk management requires evaluation by a qualified cardiologist or internist. Do not start, stop, or modify any cardiovascular or weight loss medication without consulting your prescribing physician. The SELECT trial findings reflect outcomes in a specific study population and may not apply to all individuals with overweight or obesity.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Tony, a 59-year-old retiree from Phoenix, had his first heart attack at 55. His cardiologist put him on a statin, aspirin, and a beta-blocker. He lost 12 pounds through diet changes. Then life got busy, and the weight came back. By 2023 he was carrying 247 pounds on a 5\u201910″ frame, a BMI of 35.4. His cardiologist brought up Wegovy. Not for the weight, or at least not only for the weight. \u201cShe said there was a trial that showed it actually reduces heart attacks in people like me,\u201d Tony recalled. \u201cI thought she was talking about a diabetes drug.\u201d She wasn\u2019t. The trial his cardiologist was referencing had just been published in the New England Journal of Medicine and had changed how cardiologists think about a drug most people still associate with weight loss. The SELECT Trial: What It Studied and Why It Matters The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial, known as SELECT, was not a weight loss study. It was a cardiovascular outcomes trial designed around one question: does semaglutide 2.4 mg reduce the incidence of serious heart events in overweight or obese adults who already have cardiovascular disease, but do not have diabetes? That distinction is critical. Prior cardiovascular outcomes trials for GLP-1 medications, including LEADER and SUSTAIN-6, enrolled patients with type 2 diabetes. Their cardiovascular benefits were significant, but they left open the question of whether the drug itself was doing the work or whether better blood sugar control was the driver. SELECT removed diabetes from the equation entirely. The trial enrolled 17,604 adults across 41 countries. All participants had a BMI of 27 or above, pre-existing cardiovascular disease (prior heart attack, prior stroke, or symptomatic peripheral arterial disease), and no history of diabetes. Participants were randomized to semaglutide 2.4 mg weekly or placebo. Median follow-up was 3.3 years\u00b9. The Results The primary endpoint was a composite of major adverse cardiovascular events: cardiovascular death, nonfatal heart attack, or nonfatal stroke. The results, published in the New England Journal of Medicine in November 2023: Outcome Semaglutide Placebo Hazard Ratio MACE (primary endpoint) 6.5% 8.0% 0.80 (95% CI 0.72-0.90) Cardiovascular death 2.5% 3.0% 0.85 (95% CI 0.71-1.01) Nonfatal heart attack 3.6% 4.8% 0.72 (95% CI 0.61-0.85) Nonfatal stroke 1.3% 1.5% 0.81 (95% CI 0.60-1.08) A 20% relative risk reduction in major cardiovascular events (HR 0.80, 95% CI 0.72-0.90, p less than 0.001). The number needed to treat to prevent one cardiovascular event over 3.3 years was approximately 67 patients. The benefit appeared consistent across subgroups, including age, sex, body weight, and region. Importantly, it emerged well before meaningful weight loss had accumulated, raising questions about whether the mechanism extends beyond adiposity reduction alone\u00b2. The FDA Response: A New Indication In March 2024, the FDA approved Wegovy (semaglutide 2.4 mg) for the reduction of serious cardiovascular events in adults with established cardiovascular disease and overweight or obesity, making it the first weight loss medication to ever receive a cardiovascular risk reduction indication. This matters clinically and symbolically. For decades, weight loss drugs were approved purely on the basis of weight outcomes. SELECT changed the regulatory framing: semaglutide is now approved not only to reduce body weight, but to reduce the likelihood that a patient with heart disease dies from it or has another event. For prescribing physicians, this creates a new category of patient who has a clear indication for semaglutide even when weight loss is not the primary goal. How Might GLP-1 Protect the Heart? Weight loss is part of the story, but probably not all of it. Inflammation reduction. Systemic inflammation drives atherosclerotic plaque development and instability. GLP-1 receptor activation has demonstrated direct anti-inflammatory effects on vascular endothelium and macrophages within atherosclerotic plaques, independent of weight changes. In SELECT, participants receiving semaglutide showed reductions in high-sensitivity CRP (a key inflammatory marker) that exceeded what weight loss alone would predict\u00b3. Blood pressure and lipid improvements. Across SELECT, semaglutide-treated participants showed modest but consistent reductions in systolic blood pressure and improvements in lipid profiles, both established cardiovascular risk factors. Direct cardiac effects. GLP-1 receptors are expressed on cardiomyocytes and vascular smooth muscle. Pre-clinical studies suggest GLP-1 receptor activation may improve cardiac function directly, reduce oxidative stress in cardiac tissue, and promote favorable remodeling after ischemic injury. These mechanisms are active research areas; they have not been definitively established in humans. Plaque stabilization. Some researchers hypothesize that GLP-1 receptor activation stabilizes atherosclerotic plaques, making them less likely to rupture and cause acute events. This is consistent with the early divergence of event curves in SELECT, which began separating before substantial weight loss was achieved. What SELECT Does and Doesn\u2019t Tell Us What it shows: Semaglutide 2.4 mg produces a clinically meaningful, statistically robust reduction in major cardiovascular events in people with obesity and established cardiovascular disease who do not have diabetes. This benefit is real and FDA-recognized. What it doesn\u2019t show: SELECT does not establish whether semaglutide prevents a first cardiovascular event in lower-risk populations. The trial enrolled patients with established CVD, not those with risk factors only. The cardiovascular benefit in primary prevention settings remains an open research question. Tirzepatide: The SURMOUNT-CVOT trial is examining tirzepatide\u2019s cardiovascular effects and will provide comparable data for the dual GLP-1\/GIP agonist within the next several years. SELECT\u2019s findings cannot be automatically extended to tirzepatide. Weight loss is still meaningful: Even setting aside cardiovascular outcomes, the SELECT participants lost an average of 9.4% of body weight at two years on semaglutide versus 0.9% on placebo. For someone at Tony\u2019s starting weight, that\u2019s approximately 23 pounds of real weight loss with real metabolic benefits. Who Should Be Having This Conversation With Their Doctor? The SELECT population is a specific group: adults with BMI 27 or above and a prior cardiovascular event (heart attack, stroke, or symptomatic peripheral artery disease), without type 2 diabetes. These patients now have an FDA-approved cardiovascular indication for semaglutide, not just an obesity treatment rationale. If you have a prior heart attack or stroke, carry excess weight, and are not diabetic, SELECT established that semaglutide can reduce your risk of another event. That conversation belongs in the cardiologist\u2019s office as much as the primary care office. For patients already on semaglutide for weight or metabolic reasons who also have established CVD: the SELECT data suggests you may be receiving cardiovascular protection alongside the metabolic benefit, something worth discussing with your cardiologist when reviewing your overall risk management plan. Key Takeaway SELECT enrolled 17,604 adults with obesity and pre-existing cardiovascular disease but no diabetes, and found that semaglutide 2.4 mg produced a 20% relative risk reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) over 3.3 years versus placebo. In March 2024, the FDA approved Wegovy for cardiovascular risk reduction, the first time a weight loss medication has received this designation. The benefit likely reflects a combination of weight loss, inflammation reduction, blood pressure improvement, and possible direct vascular effects. For patients with established cardiovascular disease and obesity who are not diabetic, semaglutide now carries a cardiovascular indication, not just a weight loss one. Category GLP-1, Semaglutide, Cardiovascular Risk, Heart Attack, SELECT Trial, Wegovy, Obesity, Heart Disease, MACE, FDA Approval, Cardiovascular Outcomes References \u00b9 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232. \u00b2 SELECT trial subgroup analyses and early event curve divergence. New England Journal of Medicine supplementary data. 2023. \u00b3 Anti-inflammatory mechanisms of GLP-1 receptor agonism: vascular endothelium, macrophage polarization, and CRP reduction. Journal of the American College of Cardiology. 2024. \u2074 FDA approves Wegovy for reduction of cardiovascular events in adults with obesity or overweight and established cardiovascular disease. FDA Press Release. March 8, 2024. \u2075 GLP-1 receptor expression in cardiomyocytes and vascular smooth muscle: pre-clinical and translational evidence for direct cardiac effects. Circulation. 2023. Disclaimer This article is for educational purposes only and is not medical advice. Semaglutide\u2019s cardiovascular indication applies specifically to adults with established cardiovascular disease and overweight or obesity without type 2 diabetes. Individual cardiovascular risk management requires evaluation by a qualified cardiologist or internist. Do not start, stop, or modify any cardiovascular or weight loss medication without consulting your prescribing physician. The SELECT trial findings reflect outcomes in a specific study population and may not apply to all individuals with overweight or obesity.<\/p>\n","protected":false},"author":2,"featured_media":441,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-440","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-en"],"_links":{"self":[{"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/posts\/440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/comments?post=440"}],"version-history":[{"count":1,"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/posts\/440\/revisions"}],"predecessor-version":[{"id":442,"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/posts\/440\/revisions\/442"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/media\/441"}],"wp:attachment":[{"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/media?parent=440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/categories?post=440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.altrx.com\/blogs\/wp-json\/wp\/v2\/tags?post=440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}